Skip to main content
Article thumbnail
Location of Repository

Six years survival on imatinib with no disease progression after diagnosis of metastatic duodenal gastrointestinal stromal tumour: a case report

By Sayantan Bhattacharya, Amit Kumar Choudhury, Srinivasan Ravi, John R. Morrissey and G. (George) Mathew


Introduction: A duodenal Gastrointestinal Stromal Tumour (GIST) is a rare finding and until recently advanced disease had a poor prognosis. A PubMed search revealed no reports of more than five years survival of inoperable GIST on chemotherapy with WHO performance status zero.\ud Case Presentation: A 68 year old female was diagnosed with unresectable GIST in the duodenum with metastasis to liver, pancreas and omentum in November 2001. She was\ud commenced on imatinib mesylate (Glivec) chemotherapy. This case report was prepared from the medical records and radiology reports. She had good tolerance with stable disease. After six years her CT scan showed no disease progression and her WHO performance status was zero.\ud Conclusion: This report supports the view that imatinib is a safe and effective drug in controlling\ud disease progression in advanced metastatic GIST and plays an important role in improving the patient's quality of life

Topics: RC
Publisher: BioMed Central Ltd.
Year: 2008
OAI identifier:

Suggested articles


  1. (2006). A: Prognostic value of KIT exon 11 deletions in GISTs. Gastroenterology doi
  2. (2007). CD: The role of KIT in the management of patients with gastrointestinal stromal tumours. Human Pathology doi
  3. for Clinical Excellence: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours.
  4. (2006). Gastrointestinal stromal tumor. A study of 158 cases: clinicopathological features and prognostic factors.
  5. (2006). Gastrointestinal stromal tumors with KIT exon11 deletions are associated with poor prognosis. Gastroenterology doi
  6. (2006). Gastrointestinal stromal tumors: pathology and prognosis at different sites. Seminars in diagnostic pathology doi
  7. (2006). JA: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. doi
  8. (2002). JA: Prognostic value of KIT mutation type, mitotic activity and histologic subtype in gastrointestinal stromal tumors. doi
  9. (2005). Research: Deletions affecting codons 557–558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). doi
  10. (2006). Yamagishi H: Long-term survival of a case with multiple liver metastases from duodenal gastrointestinal stromal tumor drastically reduced by the treatment with imatinib and hepatectomy.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.